Sanofi Pasteur dengue vaccine approved for Philippines

Particles of the dengue fever virus.
Particles of the dengue fever virus. | Courtesy of the CDC

A vaccine for the dengue virus developed by Sanofi Pasteur has been approved for use in the Philippines.

The Philippine Food and Drug Administration has officially approved Dengvaxia to be used against all serotypes of the virus for those between nine and 45 years of age. The company reports that the Philippines is the first Asian country to approve the vaccine, which is the first of its kind to reach the area.

According to the company, approximately 67 million people are affected by the virus in Asia. The region currently has the highest levels of disease burden from dengue, consisting of 70 percent of the global burden.

"Prevention of dengue is an urgent and growing medical priority in the Philippines," May Montellano, president of the Philippine Foundation for Vaccination, said. "Vaccination is widely accepted as one of the most cost-effective ways to reduce the spread of infectious diseases like dengue. The approval of Dengvaxia, the world's first dengue vaccine in the Philippines, will be a critical addition to the ongoing public education and vector control efforts currently directed towards dengue prevention in our country."

Dengue fever is typically spread through mosquito bites and is endemic to tropical and subtropical regions across the globe.

Organizations in this Story

Sanofi Pasteur

Want to get notified whenever we write about Sanofi Pasteur ?
Next time we write about Sanofi Pasteur, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.